Incentivizing Access to New Drugs in Psychiatry: Exploration of a Subscription Payment Approach to Overcome Barriers to European Launch

Author(s)

Heather Wieffer, PhD, Harrison Davis, PhD, Catherine Kielar, PhD.
Avalere Health, London, United Kingdom.
OBJECTIVES: Several psychiatric drugs with new therapeutic targets have launched in the last five years in the US, providing patients with additional treatment options, but not in Europe. One likely factor is anticipated challenging pricing and access in public payer-dominated markets for these indications. We considered whether an innovative payment model used for antibiotics could support patient access.
METHODS: Key features of subscription payment models were identified and used to develop a hypothetical scenario applied to psychiatric drugs for patients failed by standard-of-care therapies. Benefits and challenges of this scenario were explored.
RESULTS: In this hypothetical scenario, manufacturers would receive a set annual payment to supply drugs on demand, such to be commercially acceptable. Patient access would be permitted in the case that criteria for failure of standard-of-care therapy are fulfilled. Developers may be incentivized to launch, given guaranteed income, without unviable price or volume restrictions, and to not seek use beyond eligibility criteria. Health systems would benefit from access to newer alternatives to benefit patients, without financial risk of over-use. However, additional challenges are identified, over the model’s application for antibiotics. Definition of treatment failure and its application in clinical practice would be critical to avoid unanticipated volumes but is more complex and subjective than for infections. Evidence challenges specific to psychiatry indications would still impact on initial assessment of clinical benefit to inform contracting, and any subsequent real-world monitoring to inform continuation.
CONCLUSIONS: Although the key driver for model use for antibiotics (avoiding resistance) is not the case for psychiatry, a subscription model may be attractive through incentivizing launch while limiting payer risk, with both sides aligned to restrict use to when needed. However, this would not avoid uncertainty in clinical benefit (subpopulation and magnitude) that would require greater complexity in implementation.

Conference/Value in Health Info

2025-11, ISPOR Europe 2025, Glasgow, Scotland

Value in Health, Volume 28, Issue S2

Code

HPR121

Topic

Health Policy & Regulatory

Topic Subcategory

Risk-sharing Approaches

Disease

Mental Health (including addition)

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×